And the agency approved an updated indication for sotatercept (Winrevair) in pulmonary arterial hypertension (PAH) to include a reduction in PAH-related events such as hospitalization, lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback